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CAse RepoRt
A 19 year old female presented with spontaneous intra-oral 
bleeding of two days duration. The patient reported that 
she was, until recently, in good general health and also that 
she had an uncomplicated parturition three years ago. She 
recently started noticing blood in her stools and felt increas-
ingly lethargic. There was no history of trauma or intra-oral 
intervention that may have initiated the bleeding. 
The clinical examination revealed marked pallor of the fa-
cial skin and multiple small petechiae were seen on both of 
her forearms. The intra-oral examination identified marked 
halitosis and multiple haemorrhagic lesions with a variable 
appearance, being plaque-like on the lip, nodular on the 
tongue and fungating and exophytic on the palate and in 
the retromolar regions. Even delicate manipulation of the 
tissues produced profuse bleeding (Figures 1-3). 
Due to her general weakness and the excessive bleeding 
she was admitted to the local tertiary hospital with the 
suspicion of thrombocytopenia and possible HIV infection. 
The reason for the latter suspicion was that some of the 
oral lesions clinically resembled Kaposi sarcoma. Upon 
admission, the following vital signs were recorded: 
blood pressure (BP) 97/52; heart rate 140 beats/min; 
temperature 36˚C; random blood glucose 8.7mmol/L; 
ward haemoglobin (Hb) 6.4g/dL; and weight 55kg. Venous 
blood was drawn and submitted for a full blood count, INR, 
direct Coombs test and test for HIV infection. There was a 
marked difference between the haemoglobin level taken in 
the ward and that from the blood test result with the latter 
being much lower. The results are tabulated in Table 1. The 
blood tests confirmed HIV infection and the suspicion of 
oral Kaposi sarcoma was thus vindicated. In consultation 
with the Department of Haematology of the hospital, 
Evans syndrome and idiopathic thrombocytopenia were 
added to the differential diagnosis. 
The marked anaemia and thrombocytopenia on the 
day of admission necessitated immediate transfusion of 
leukocyte depleted packed red blood cells (LDPRBC) 
and platelets. This was done under the supervision of the 
attending haematologist and, on Day 1 post-admission, 
she received three units of LDPRBC and two mega-units 
of platelets. Blood tests subsequent to the transfusion 
revealed that her red cell count (2.92 x 1012/L), Hb (8.4 g/
dL) and platelet count (2 x 109/L) remained low. On Day 
2 she received a further two units of LDPRBC and one 
mega-unit of platelets which resulted in her reporting 
feeling better. At this time, her vital signs were noted as 
follows: BP 109/65, heart rate 94 and temperature 36.6˚C. 
On day 3, under the guidance of the haematologist, 
intravenous infusion of a 3% solution of immune globulin 
(Polygam®) was commenced at a rate of 1g/kg body 
weight over 90 minutes. As a result of the high probability 
of side effects with the use of Polygam®, she was also 
prescribed a stat dose of 100 mg of solumedrol and 25mg 
phenergan, administered intravenously, as prophylaxis. 
She received two further doses of Polygam® on Days 4 
and 5. A clinical examination on Day 6 revealed that there 
was no intraoral bleeding, no increase in the size of the 
petechiae and that the melena had resolved. A further 
two units of LDPRBC and a mega-unit of platelets were 
administered due to the blood results still indicating a 
low haemoglobin level (6.9 g/dL) and platelet count (3 x 
109/L). The lesions, however, had regressed to such a 
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ACRonyMs
AIHA:  Autoimmune haemolytic anaemia  
bp:  Blood pressure
eV:  Evans syndrome
Hb:  Haemoglobin
HIV:  Human immunodeficiency virus
InR:   International normalized ratio (a measure of 
prothrombin time)
Itp:  Immune-induced thrombocytopaenia
ldpRbC:  Leukocyte depleted packed red blood cells
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degree that the differential diagnosis of Kaposi sarcoma 
could then be excluded. Subsequent blood tests revealed 
that the direct Coombs test (direct antiglobulin test) was 
again positive (1+ strong micropositive), in the presence 
of thrombocytopenia (4 x 109/L), thus the diagnosis of 
Evans syndrome. 
Treatment for Evans syndrome was then initiated and in-
cluded: azathioprine (150 mg per os daily for three days) 
and prednisone (60 mg per os daily). Her red cell count 
(3.48 x 1012/L) and haemoglobin (10.0 g/dL) had both im-
proved but her platelet count remained low (7 x 109/L). 
By Day 8 post-admission, the lesions had nearly totally 
regressed and her platelet count improved to 46 x 109/L. 
She was subsequently discharged and prednisone was 
prescribed (60 mg/day for one month) and the one month 
follow-up examination revealed total regression of all le-
sions. Her red cell count (3.98 x 1012/L), haemoglobin 
(11.5 g/dL) and platelet count (108 x 109/L) had all im-
proved. The prednisone was continued for the next month 
at a dosage of 40 mg/day and, at that time, the patient’s 
pallor and lethargy had both dissipated and she reported 
feeling in good health. Her blood results were within the 
normal range (red cell count: 3.88 x 1012/L; haemoglobin: 
11.2 g/dL; platelets: 210 x 109/L). The prednisone dos-
age was then decreased to 35 mg/day and tapered by 5 
mg/week over the following 6 weeks. Due to the very low 
CD4+ cell count, HAART was then commenced and at 
her follow up visit after a further two months, the patient 
had no oral or skin lesions and was otherwise stable. She 
is currently on a regular recall schedule and at the time of 
publication she remained stable without recurrence of the 
intra-oral haemorrhagic lesions (Figure 4).  
dIsCussIon
Evans syndrome (ES) is an uncommon autoimmune disor-
der and is defined by the simultaneous or sequential de-
velopment of autoimmune haemolytic anaemia (AIHA) and 
immune-induced thrombocytopenia (ITP), with a positive 
direct antiglobulin test (also known as the Coombs test), 
in the absence of known underlying aetiology. At times 
the condition may be accompanied by immune neutrope-
nia.1,2 The condition was first described in 1951 by Robert 
Evans, based on a series of 24 patients who presented 
with a spectrum of these clinical features.1 ES is a rare 
condition and is diagnosed in only 0.8% to 3.7% of all 
patients presenting with either ITP or AIHA at onset.3 It is 
considered a diagnosis of exclusion and as it suggests an 
advanced state of immune dysregulation, other autoim-
mune conditions such as systemic lupus erythematosus 
(SLE),4 lymphoproliferative disorders,5,6 primary immuno-
deficiencies7, collagen vascular diseases and autoimmune 
lymphoproliferative syndrome (ALPS) should be exclud-
ed.8-11 In addition to the presence of ITP and AIHA seen 
in Evans syndrome, immunologically, there is a reversal in 
the CD4:CD8 ratio, 3 (normally ≥1) which is an indicator of 
severe immune dysregulation. This occurs as a result of a 
decrease in CD4 cells (T helper cell) with a compensatory 
increase in CD8 cells (a class of T regulatory cells). The 
reversal also occurs in uncontrolled HIV infection, how-
ever, in the case presented above only the CD4 count was 
available on the day of admission so no information on this 
ratio was available.
Haematological abnormalities such as anaemia, throm-
bocytopenia and neutropenia are commonly observed in 
patients infected with HIV.12-14 Pancytopenias are frequent 
Figure 1: At the initial consultation the patient 
presented with macular and papular lesions on 
the lower labial mucosa. Note the bruising and 
gingival bleeding.
Figure 3: A mirrored image of the palate shows 
signs of excessive gingival bleeding and two mid-
palatal haemorrhagic vesicles can also be seen.
Figure 2: Haemorrhagic lesions were seen on 
the left buccal mucosa and retromolar area with 
signs of excessive bleeding.
Figure 4: A mirrored image of the patient’s palate, 
approximately 3 months after initial presentation, showed 
total resolution of the haemorrhagic lesions.
table 1: The initial blood test results of the patient presenting with 
haemorrhagic lesions of the oral cavity.
test normal value patient result
Blood smear Thrombocytopenia
Occasional nucleated red cells
Mild polychromasia
Absolute neutropenia
White cell count 4-10 x109/L 11.12 x 109/L
Red cell count 3.80 – 4.80 x109/L 1.92 x 109/L
Haemoglobin 12.0 – 15.0g/dL 4.9 g/dL
Platelet count 178 – 400 x109/L 12 x 109/L
INR 1.2
Direct Coombs test 
(Direct Antiglobulin Test)
Polyspecific: 2+ micro positive
IgG:     2 + micro positive
HIV Reactive with CD4+ count of 
280 cells/µL
74 >
complications of HIV and may be the result of a bone mar-
row production defect or due to increased peripheral loss 
or destruction of blood cells. These abnormalities may oc-
cur as a result of the HIV infection itself or as a result of 
HIV-associated infections or malignancies, and may also 
arise as a consequence of the therapy used for the HIV 
infection.15 Numerous studies have demonstrated that a 
positive Coomb’s test occurs in patients with HIV, up to an 
incidence rate of 21%, but frank haemolysis is infrequently 
reported in such cases.16 HIV-associated thrombocytope-
nia has also been reported based on the presence of anti-
bodies directed against membrane proteins as well as ad-
herence of immune complexes to platelets,16 however, ES 
is rarely associated with HIV infection with only a few cases 
having been reported.17,18. To the best of our knowledge, the 
case presented above is unique in the sense that ES was 
the first presenting sign of an underlying HIV infection. 
The management of Evans syndrome is challenging due 
to the fact that it is characterised by periods of remission 
and exacerbation and the response to treatment varies 
within the same individual.3 First-line therapy in the 
management of ES includes the use of corticosteroids and/
or intravenous immunoglobulin. In the acute phase, blood 
and/or platelet transfusions are required as symptomatic 
management. In the case presented in this paper the use 
of corticosteroids was initially avoided because of the 
delayed final diagnosis and the initial suspicion of Kaposi 
sarcoma. (Corticosteroids are contraindicated in cases of 
Kaposi sarcoma because of the possibility of causing an 
exacerbation of the lesion by inducing expression of latent 
Human Herpes Virus 8.)19 
Second-line therapies for ES include the use of immuno-
suppressive agents (cyclosporin, mycophenolate mofetil 
and danazol), monoclonal antibodies (rituximab) and 
chemotherapy (vincristine). Splenectomy may also be 
considered as second line therapy.3 In non-responsive 
cases, third-line therapy may include autologous or allo-
genic stem cell transplantation but it does not have a reli-
able outcome, largely due to the relatively high mortality 
and failure rate in ES.3
ConClusIon
The significance of oral lesions as presenting features of 
HIV infection and as markers for the progression of im-
munosuppression is well documented. A unique case is 
presented above where the oral lesions associated with 
Evans syndrome lead to the diagnosis of a co-existing HIV 
infection. Normally, HIV-associated oral lesions present as 
opportunistic infectious lesions but, in this case, it pre-
sented as the oral lesions of a blood dyscrasia. Although 
other publications have reported on the co-existence of 
Evans Syndrome and HIV infection, as far as could be as-
certained, the present case is the only one to date where 
Evans syndrome was the presenting condition. ES is a 
manifestation of severe immune dysregulation and in cas-
es where immune-mediated destruction of blood cells are 
apparent, the presence of a co-existing or underlying HIV 
infection should be considered. 
It thus begs the question: should Evans syndrome be add-
ed to the list of presenting conditions/lesions for HIV/Aids? 
In view of the case presented here, it certainly seems to 
be appropriate. 
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